Pretreatment pregnancy testing under iPLEDGE in 2026 means two negative pregnancy tests in a medical setting before your teen takes the first isotretinoin dose. Parents can verify the test locations, birth-control timing, consent signatures, and pickup window before treatment starts. iPLEDGE is the FDA safety program for isotretinoin, a drug that treats severe acne. Isotretinoin can cause severe birth defects and miscarriage even after short-term exposure, so pregnancy must be avoided before, during, and for one month after treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why two tests come before the first dose
- Where pretreatment tests must happen
- What changes in August 2026
- Checklist for parents before the first dose
- How the 7-day pickup window works
Why two tests come before the first dose
Teens who can become pregnant must have two negative pregnancy tests before the first prescription. FDA states this rule in its February 2026 iPLEDGE update set, described in the FDA non-compliance policy document. A negative test is also required before each monthly dispense.
The first test screens for existing pregnancy. The second test confirms the result close to treatment start. Both must be negative before the pharmacy dispenses the drug.
Where pretreatment tests must happen
All testing required before the first dose must occur in a medical setting. That includes the prescriber office, clinic, or laboratory, and covers both the initial screening test and the confirmatory test. FDA explained this setting rule in the FDA medical-organizations letter.
Home testing does not count for pretreatment checks. During and after treatment, the prescriber may allow home testing. Pretreatment testing still requires a medical setting.
What changes in August 2026
FDA approved iPLEDGE modifications on Feb. 9, 2026 to reduce burden while maintaining fetal protection.
Implementation follows 180 days later, in mid-August 2026, according to the Drugs.com report on the FDA announcement. The core safeguards stay in place. Two pretreatment tests, contraception or abstinence, consent, enrollment, and monthly testing remain required.
Checklist for parents before the first dose
Confirm enrollment is complete before the pharmacy fills the prescription. For a patient under 18 who can become pregnant, both patient and parent or guardian must complete the informed consent about birth defects, with a doctor signature.
Use this check at the clinic: Birth-control timing matters as much as test results. Two effective forms used together, or continuous abstinence, must cover at least one month before starting, the full treatment period, and one month after stopping.
- Test 1 completed in prescriber office, clinic, or lab, with negative result recorded
- Test 2 completed in medical setting, with negative result confirmed
- Two birth-control forms used together for at least one month, or continuous abstinence committed for the same period
- iPLEDGE enrollment finished and consent forms signed by teen, parent or guardian, and doctor
- Monthly test and 7-day pickup plan understood for refills
How the 7-day pickup window works
The prescription must be picked up within a 7-day window after pregnancy testing. Plan transportation, school absence, and pharmacy hours around that short window.
If the window is missed, the prior 19-day lockout was eliminated. A repeat pregnancy test can be done immediately to restart the pickup clock.